Skip to content

Study · Measured the body's own peptide · 1980

4 results

Abnormalities of vasoactive intestinal polypeptide-containing nerves in Crohn's disease.

Bishop AE, Polak JM, Bryant MG, Bloom SR, Hamilton S

Gastroenterology1 Nov 1980Cited by 106 (Europe PMC)

PMID7419008 (opens in a new tab)DOI10.1016/0016-5085(80)90441-2 (opens in a new tab)PepBankPUB-07419008
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Natural levels measured4

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelObservational studyOther

    In patients with Crohn's disease, the normal pattern of slender VIP-containing nerve fibres was lost in all 17 patients and was replaced by thickened, more intensely immunostained fibres, unlike in controls.

    In plain wordsIn people with Crohn's disease, the body's own VIP nerve fibres looked thicker and different from the normal pattern seen in controls.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    MixedPattern of VIP-containing nerve fibres in Crohn's disease
    Study

    n = 17

    Comparator
    Controls (uninvolved gut from carcinoma resection, jejunoileal bypass specimens, and four of six ulcerative colitis specimens)
    Outcome group
    Endogenous peptide levels · Gastrointestinal

    Source sentences

    Summary
    In contrast, this characteristic pattern was lost in all 17 patients with Crohn's disease, the pattern being replaced by thickened and more intensely immunostained fibers.
    1 context sentence
    Summary · context
    The possible involvement of nerves containing vasoactive intestinal polypeptide in Crohn's disease was investigated by immunocytochemistry and radioimmunoassay of specimens from 17 patients with well-defined clinical and histologic features of the disease.

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

  2. 02HumanEndogenous levelObservational studyOther

    In patients with Crohn's disease, the abnormal VIP nerve pattern was found in the mucosa and submucosa, and in 13 cases it was transmural, involving both nerve plexuses and the muscle layers.

    In plain wordsIn people with Crohn's disease, the body's own VIP nerve changes reached through the whole gut wall in 13 cases.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableTransmural extent of abnormal VIP nerve pattern
    Study

    n = 17

    Outcome group
    Endogenous peptide levels · Gastrointestinal

    Source sentences

    Summary
    These changes were consistently found in the mucosa and submucosa, and in 13 of the Crohn's disease cases, the abnormal pattern was totally transmural, involving both the myenteric and submucous plexus as well as the muscle layers.
    1 context sentence
    Summary · context
    The possible involvement of nerves containing vasoactive intestinal polypeptide in Crohn's disease was investigated by immunocytochemistry and radioimmunoassay of specimens from 17 patients with well-defined clinical and histologic features of the disease.

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

  3. 03HumanEndogenous levelObservational studyOther

    In gut specimens, VIP content measured by radioimmunoassay was more than 200% higher in Crohn's disease than in ulcerative colitis (P < 0.001).

    In plain wordsIn gut tissue, the body's own VIP was much higher in Crohn's disease than in ulcerative colitis.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseVIP tissue content in Crohn's disease versus ulcerative colitis
    Study

    n = 17

    Comparator
    Ulcerative colitis
    Outcome group
    Endogenous peptide levels · Gastrointestinal

    Measurements

    VIP content
    294 pmol/g wet wt
    Crohn's disease
    VIP content
    93 pmol/g
    ulcerative colitis

    Source sentences

    Summary
    There was a > 200% increase in VIP content, as determined by radioimmunoassay, in Crohn's disease (294 +/- 29 pmol/g wet wt, mean +/- SEM) in comparison with (a) ulcerative colitis (93 +/- 5 pmol/g [P < 0.001]), and (b) controls consisting of carcinoma resection (108 +/- 39) and bypassed gut from ob…
    1 context sentence
    Summary · context
    The possible involvement of nerves containing vasoactive intestinal polypeptide in Crohn's disease was investigated by immunocytochemistry and radioimmunoassay of specimens from 17 patients with well-defined clinical and histologic features of the disease.

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

  4. 04HumanEndogenous levelObservational studyOther

    In gut specimens, VIP content measured by radioimmunoassay was higher in Crohn's disease than in controls from carcinoma resection and bypassed gut from obese patients (P < 0.001).

    In plain wordsIn gut tissue, the body's own VIP was much higher in Crohn's disease than in control gut tissue.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseVIP tissue content in Crohn's disease versus controls
    Study

    n = 17

    Comparator
    Controls (carcinoma resection and bypassed gut from obese patients)
    Outcome group
    Endogenous peptide levels · Gastrointestinal

    Measurements

    VIP content
    294 pmol/g wet wt
    Crohn's disease
    VIP content
    108 pmol/g
    carcinoma resection controls
    VIP content
    86 pmol/g
    bypassed gut from obese patients

    Source sentences

    Summary
    There was a > 200% increase in VIP content, as determined by radioimmunoassay, in Crohn's disease (294 +/- 29 pmol/g wet wt, mean +/- SEM) in comparison with (a) ulcerative colitis (93 +/- 5 pmol/g [P < 0.001]), and (b) controls consisting of carcinoma resection (108 +/- 39) and bypassed gut from ob…
    1 context sentence
    Summary · context
    The possible involvement of nerves containing vasoactive intestinal polypeptide in Crohn's disease was investigated by immunocytochemistry and radioimmunoassay of specimens from 17 patients with well-defined clinical and histologic features of the disease.

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.